MicroPort EP(688351)2024-10-24 07:37Group 1: Financial Performance - As of Q3 2024, the company achieved a revenue of 291 million CNY, reflecting a year-on-year growth of 23.2% [1] - In Q3 2024, the company reported a revenue of 92.5 million CNY, showing a slight decline compared to the previous quarter [1] - Overseas revenue increased by over 20% year-on-year, despite domestic revenue being affected by changes in distributors and delayed revenue recognition for some overseas projects [1] Group 2: Surgical Volume and Product Performance - In Q3 2024, the company performed approximately 5,000 surgeries, with over 6,000 surgeries conducted in total for three-dimensional electrophysiology [2] - The company reported over 3,000 surgeries in Beijing, Tianjin, and Hubei, with one-third of these surgeries focused on atrial fibrillation treatment [2] - The company’s high-value consumables have seen increased usage in major medical centers, contributing to revenue growth [2] Group 3: Market Expansion and Product Registration - The company has successfully bid for multiple products in the high-value consumables category in the Beijing medical institutions' DRG payment and electrophysiology procurement [2] - The overseas market revenue is significantly high, particularly in regions like the Middle East, Russia, and the EU, driven by new country openings and product introductions [2] - The pressure catheter and magnetic positioning ring lung catheter have received EU CE certification, with plans for further product registrations [2][3] Group 4: Innovative Technology Development - The company’s self-developed pressure pulse catheter has completed clinical enrollment and is currently undergoing special review by the National Medical Products Administration (NMPA) [3] - The second-generation PFA product from the affiliated company, Shangyang Medical, is expected to receive NMPA registration by mid-2025 [3]